PPLPHARMA.NS Piramal Pharma Ltd.
Price history
Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.
Technical indicators
ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.
MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.
Delivery volume
| Date | Traded Qty | Delivery Qty | Delivery % |
|---|---|---|---|
| 2026-08-28 | 5418446 | 2263549 | 41.77% |
| 2026-08-27 | 4647834 | 1975595 | 42.51% |
| 2026-08-26 | 2678764 | 1248733 | 46.62% |
| 2026-08-25 | 1716798 | 551940 | 32.15% |
| 2026-08-24 | 2681269 | 1278596 | 47.69% |
| 2026-08-21 | 4572601 | 2246713 | 49.13% |
| 2026-08-20 | 4134099 | 2052516 | 49.65% |
| 2026-08-19 | 2926756 | 946667 | 32.35% |
| 2026-08-18 | 5337954 | 1757194 | 32.92% |
| 2026-08-17 | 2912134 | 1079919 | 37.08% |
| 2026-08-14 | 11439262 | 2058894 | 18.00% |
| 2026-08-13 | 2244388 | 867619 | 38.66% |
| 2026-08-12 | 2720946 | 1044063 | 38.37% |
| 2026-08-11 | 3675806 | 1552911 | 42.25% |
| 2026-08-10 | 9027584 | 3356035 | 37.18% |
| 2026-08-07 | 4611692 | 2145739 | 46.53% |
| 2026-08-06 | 7183683 | 2873172 | 40.00% |
| 2026-08-05 | 9351752 | 4789666 | 51.22% |
| 2026-08-04 | 7037103 | 2584744 | 36.73% |
| 2026-08-03 | 7051612 | 2495028 | 35.38% |
Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers PPLPHARMA.NS to fetch more history.
Insider trading activity
No insider-trading disclosures on file — run python manage.py refresh_insider_trades --tickers PPLPHARMA.NS. (No stored disclosures may mean none have been fetched yet, or that NSE has genuinely published none for this company.)
Extract this company (financials + ratios + citations): CSV · XLSX
Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score
Ratios
This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.
Growth & earnings trend
Revenue & Profit CAGR
Operating Margin Trend
ROCE Trajectory
Earnings Quality
Needs net profit and CFO for 3+ stored years; only 2 on file.
Sector-Relative Percentile (Healthcare)
Quarterly trend
| Metric (to shareholders basis) | Q4 FY2023-24 | Q1 FY2024-25 | Q2 FY2024-25 | Q3 FY2024-25 | Q4 FY2024-25 | Q1 FY2025-26 | Q2 FY2025-26 | Q3 FY2025-26 | Q4 FY2025-26 | Q1 FY2026-27 | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,552.36 Cr. | ₹1,951.14 Cr. | ₹2,241.75 Cr. | ₹2,204.22 Cr. | ₹2,754.07 Cr. | ₹1,933.71 Cr. | ₹2,043.72 Cr. | ₹2,139.87 Cr. | ₹2,751.77 Cr. | ₹2,269.92 Cr. | RevenueFromOperations |
| Net Profit | ₹101.27 Cr. | ₹-88.64 Cr. | ₹22.59 Cr. | ₹3.68 Cr. | ₹153.50 Cr. | ₹-81.70 Cr. | ₹-99.22 Cr. | ₹-136.19 Cr. | ₹-8.82 Cr. | ₹-69.39 Cr. | ProfitLossForPeriod |
Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers PPLPHARMA.NS to fetch more.
Source document — income statement (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| ProfitOrLossAttributableToOwnersOfParent | -3259400000.0 |
| PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital | 1327160000.0 |
Source document — balance sheet (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| CurrentAssets | 71916600000.0 |
| CurrentLiabilities | 47582800000.0 |
| EquityAttributableToOwnersOfParent | 81626200000.0 |
| BorrowingsCurrent + BorrowingsNoncurrent | 54954800000.0 |